Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Highlights•Nanocarriers with the ability to target tumors are being increasingly explored.•
Nanomedicine aid in maintaining a balance between efficacy and toxicity.•Recent advances …

Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-
cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient …

Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event
is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in …

Abstract Dihydroartemisinin (DHA), a first-line antimalarial drug, has demonstrated great
anticancer effects in many types of tumors, including liver cancer, glioblastoma, and …

DNA damage response (DDR) inhibitors potentiate the therapeutic efficacy in osteosarcoma
(OS) treatment. However, drug resistance, severe collateral toxicity, and poor bioavailability …

Simple Summary Recent practice-changing trials have highlighted the importance of
polyadenosine diphosphate-ribose polymerase inhibitors (PARPi) in metastatic castrate …

Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has
been going on for decades to meet the challenges of treating solid tumors with selective …

Ovarian cancer is the most common cause of death among gynecological malignancies
globally. Ovarian cancer treatment integrates debulking surgery and systemic therapy …

Simple Summary This review aims at analyzing an emergent topic regarding the possible
combined use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), anticancer drugs …